{"id":784792,"date":"2023-09-19T06:57:09","date_gmt":"2023-09-19T10:57:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/"},"modified":"2023-09-19T06:57:09","modified_gmt":"2023-09-19T10:57:09","slug":"pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/","title":{"rendered":"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ZUG, Switzerland, Sept.  19, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U2lSiKCaor93q6f4cKcQ1ScVPgxYg7iIo1fEsgQXULtUr-mfwVgKX5osIzPwQAI5m-guGlcOvUTsTs8fn_kL_w==\" rel=\"nofollow noopener\" target=\"_blank\">Pharvaris<\/a> (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023. Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m. ET.<\/p>\n<p>A live audio webcast of the 2023 Cantor Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ivufO8UZrFJySTsxCog4vRK27DLoQXeqqmm0T79kinnL5Tp4Nr4CEMQpQP4JMmfh-FFY1TrjlQdNc4jtxJv5ORDvnlCESY8FwCoeSyrAlD97Lc3zQhinKNlt4vJRnqvw8OItEJghXhPG1WqPZ7RMg3FZ3iT_MW8SE2CkzSKgoAhY4ZvO6yz0kQAsz-fjbf2M\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.pharvaris.com\/news-events\/events-presentations<\/a>. A replay will be available on Pharvaris\u2019 website for 30 days following the presentation.<\/p>\n<p>\n        <strong>About Pharvaris<\/strong><br \/>\n        <br \/>Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ivufO8UZrFJySTsxCog4ve3BV3dS9xcy_aWq5s5l1v4u5tjI48vRQ-k2D9rzTcqWKp8kvnKYnFWUTMY4KLfyCFN0Ege363l70ouVZKd8a5Y=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/pharvaris.com\/<\/a>.<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmQxMmVhMzEtNmM1Zi00ZDdmLTllYzEtNDMyNWUwOTI2MGZkLTEyMTc1MDA=\/tiny\/Pharvaris-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact\r\nMaggie Beller\r\nExecutive Director, Head of External and Internal Communications\r\nMaggie.beller@pharvaris.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023. Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m. ET. A live audio webcast of the 2023 Cantor Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https:\/\/ir.pharvaris.com\/news-events\/events-presentations. A replay will be available on Pharvaris\u2019 website for 30 days following the presentation. About Pharvaris Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-784792","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023. Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m. ET. A live audio webcast of the 2023 Cantor Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https:\/\/ir.pharvaris.com\/news-events\/events-presentations. A replay will be available on Pharvaris\u2019 website for 30 days following the presentation. About Pharvaris Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to &hellip; Continue reading &quot;Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-19T10:57:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference\",\"datePublished\":\"2023-09-19T10:57:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/\"},\"wordCount\":196,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/\",\"name\":\"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=\",\"datePublished\":\"2023-09-19T10:57:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference - Market Newsdesk","og_description":"ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023. Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m. ET. A live audio webcast of the 2023 Cantor Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https:\/\/ir.pharvaris.com\/news-events\/events-presentations. A replay will be available on Pharvaris\u2019 website for 30 days following the presentation. About Pharvaris Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to &hellip; Continue reading \"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-19T10:57:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference","datePublished":"2023-09-19T10:57:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/"},"wordCount":196,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/","name":"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=","datePublished":"2023-09-19T10:57:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNDM3MyM1ODIwNzQ3IzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-2023-cantor-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=784792"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784792\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=784792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=784792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=784792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}